edotreotide has been researched along with Lymphoma, B-Cell, Marginal Zone in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Angelberger, P; Dudczak, R; Kienast, O; Kurtaran, A; Li, M; Li, S; Raderer, M; Schima, W; Traub-Weidinger, T; Virgolini, I | 1 |
1 trial(s) available for edotreotide and Lymphoma, B-Cell, Marginal Zone
Article | Year |
---|---|
111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.
Topics: Adult; Aged; Aged, 80 and over; Citrates; False Negative Reactions; False Positive Reactions; Female; Gallium; Heterocyclic Compounds; Humans; Indium Radioisotopes; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Octreotide; Peptides, Cyclic; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2003 |